f you're working to overcome opioid dependence, you know the experience can sometimes be overwhelming. That's why the formulation of your medication should help make your experience convenient. Some patients have shared their concerns about taking SUBOXONE® (buprenorphine and naloxone) sublingual tablets (CIII), such as:
The time the tablets take to dissolve
The difficulty of traveling with them
Consider a treatment that may make your experience more comfortable and convenient.
, a new formulation of SUBOXONE, may improve your daily treatment experience. And clinical trial patients tell us they prefer SUBOXONE Film to the SUBOXONE Tablet.1a
SUBOXONE Film is indicated for long-term treatment of opioid dependence and should be used as part of a complete treatment plan that includes counseling and support.
SUBOXONE Film delivers:
An evolved patient experience
- Faster to dissolve than SUBOXONE Tablet1b
- A favorable taste rating (more than 71% of patients scored the taste as neutral or better)1c
- Individually wrapped in compact unit-dose pouches that are child-resistant1d and easy to carry1e
- Once-daily dosing (just like the SUBOXONE Tablet)2
- Clinically interchangeable with SUBOXONE Tablet, so your doctor can transition you. Your doctor should monitor you for overmedication3
Built-in support from the Here to Help® Program that can help make treatment success more likely4
Experience exclusive savings
Only SUBOXONE Film offers savings on your prescription of up to $75* per month if eligible. Download your savings card
now and take it to your next doctor appointment.
*Click here for details
Call for an appointment today
To experience SUBOXONE Film—and take advantage of the savings—you will need a prescription for SUBOXONE Film. If you haven't made an appointment yet, don't wait. Ask your doctor whether you can improve your treatment experience by changing to SUBOXONE Film
Keep in mind that physical dependence is just one part of the story. Your relationships, thoughts, and daily routines are all tied together. That's why counseling
is such a critical part of your treatment. And why the Here to Help Program may be too. Here to Help has been shown to increase the likelihood you'll stay in medication-assisted treatment, which can help lead to better treatment success.4
You should know: As with other opioids, buprenorphine can be abused. It's essential that your doctor monitor your use of SUBOXONE Film to help you achieve and maintain stability. You should also expect to make regular follow-up visits, especially if your doctor prescribes multiple refills.
The Here to Help Program
is only for people who are in treatment with SUBOXONE Film.
Know someone who is opioid dependent? Help them start their own treatment story. Tell them
about SUBOXONE Film.
The Here to Help Team
Important Safety Information
SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) is indicated for maintenance treatment of opioid dependence as part of a complete treatment plan to include counseling and psychosocial support. Treatment should be initiated under the direction of physicians qualified under the Drug Addiction Treatment Act.
SUBOXONE® (buprenorphine HCl/naloxone HCl dihydrate sublingual tablets) (CIII) is indicated for the treatment of opioid dependence.
SUBOXONE Sublingual Film and SUBOXONE Sublingual Tablets should not be used by patients hypersensitive to buprenorphine or naloxone.
SUBOXONE Sublingual Film and SUBOXONE Sublingual Tablets can be abused in a manner similar to other opioids, legal or illicit. Clinical monitoring appropriate to the patient's level of stability is essential.
Chronic use of buprenorphine can cause physical dependence. A sudden or rapid decrease in dose may result in an opioid withdrawal syndrome that is typically milder than seen with full agonists and may be delayed in onset.
SUBOXONE Sublingual Film and SUBOXONE Sublingual Tablets can cause serious life-threatening respiratory depression and death, particularly when taken by the intravenous (IV) route in combination with benzodiazepines or other central nervous system (CNS) depressants (ie, sedatives, tranquilizers, or alcohol). It is extremely dangerous to self-administer nonprescribed benzodiazepines or other CNS depressants while taking SUBOXONE Sublingual Film or SUBOXONE Sublingual Tablets. Dose reduction of CNS depressants, SUBOXONE Sublingual Film and SUBOXONE Sublingual Tablets, or both when both are being taken should be considered.
Liver function should be monitored before and during treatment.
Death has been reported in nontolerant, nondependent individuals, especially in the presence of CNS depressants.
Children who take SUBOXONE Sublingual Film or SUBOXONE Sublingual Tablets can have severe, possibly fatal, respiratory depression. Emergency medical care is critical. Keep SUBOXONE Sublingual Film and SUBOXONE Sublingual Tablets out of the sight and reach of children.
Intravenous misuse or taking SUBOXONE Sublingual Film or SUBOXONE Sublingual Tablets before the effects of full-agonist opioids (eg, heroin, hydrocodone, methadone, morphine, oxycodone) have subsided is highly likely to cause opioid withdrawal symptoms.
Neonatal withdrawal has been reported. Use of SUBOXONE Sublingual Film or SUBOXONE Sublingual Tablets in pregnant women or during breast-feeding should only be considered if the potential benefit justifies the potential risk. Caution should be exercised when driving vehicles or operating hazardous machinery, especially during dose adjustment.
Adverse events commonly observed during clinical trials and postmarketing experience for SUBOXONE Sublingual Tablets are headache, nausea, vomiting, sweating, constipation, signs and symptoms of withdrawal, insomnia, pain, and swelling of the limbs.
Adverse events commonly observed with the sublingual administration of SUBOXONE Sublingual Film are numb mouth, sore tongue, redness of the mouth, headache, nausea, vomiting, sweating, constipation, signs and symptoms of withdrawal, insomnia, pain, swelling of the limbs, disturbance of attention, palpitations, and blurred vision.
Cytolytic hepatitis, jaundice, and allergic reactions, including anaphylactic shock, have been reported.
This is not a complete list of potential adverse events associated with SUBOXONE Sublingual Film and SUBOXONE Sublingual Tablets. Please see full Product Information for a complete list.
To report an adverse event associated with taking SUBOXONE Sublingual Film or SUBOXONE Sublingual Tablets, please call 1-877-782-6966. You are encouraged to report adverse events of prescription drugs to the FDA. Visit www.fda.gov/medwatch
or call 1-800-FDA-1088.
Please see full Product Information
and Medication Guide
for SUBOXONE Film
For more about SUBOXONE Tablet, please see full Product Information